Immuno-Oncology | Specialty

Dr. Friedlander on Checkpoint Inhibitors in Second-Line Bladder Cancer Treatment

October 31st 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC

October 30th 2017

Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.

Immunotherapy, PARP Inhibitors Picking Up Steam in TNBC Pipeline

October 30th 2017

Howard "Skip" A. Burris, MD, discusses the ongoing research with PARP inhibitors and the advances in immunotherapy for patients with triple-negative breast cancer.

Novel Agents Show Impressive Activity in Hodgkin Lymphoma

October 28th 2017

Jane N. Winter, MD, discusses immunotherapy in the treatment of patients with Hodgkin lymphoma.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

CDK4/6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

October 27th 2017

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.

Progression Issues Surface With NSCLC Immunotherapy

October 27th 2017

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Dr. Winter on Checkpoint Inhibitors for Hodgkin Lymphoma

October 25th 2017

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Adjuvant Nivolumab/Ipilimumab Sustains RFS Benefit in Melanoma at 3 Years

October 22nd 2017

The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.

Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors

October 21st 2017

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

Nivolumab/Ipilimumab Combo Active for Melanoma Brain Mets

October 21st 2017

The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

Follicular Lymphoma: Audience Q&A

October 21st 2017

Follicular Lymphoma: Complexities in Combinations

October 21st 2017

Follicular Lymphoma: Considering All Novel Agents

October 21st 2017

FL: The Impact of Data from Clinical Trials

October 21st 2017

Follicular Lymphoma: Challenges in Moving Forward

October 21st 2017

Follicular Lymphoma: Optimizing Copanlisib

October 21st 2017

Follicular Lymphoma: Defining Copanlisib

October 21st 2017

Follicular Lymphoma: Overview of Treatment Options

October 21st 2017

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017